Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

Phase 2 Unknown 110 enrolled László Mangel E-Group ICT Software Informatikai Zrt. · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this clinical study is to evaluate the effectiveness and safety of selegiline plus docetaxel therapy compared to the standard of care - docetaxel therapy - among patients diagnosed with metastatic, castrate-resistant prostate adenocarcinoma.

Timeline

Start: 2020-05-18
Primary completion: 2025-02-01
Completion: 2025-02-01

Publications

Steib A, Pohoczky K, Toth N, Kormos V, Kun J, Kalai T, Mangel L, Matyus P, Helyes Z. The MAO-B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti-Androgen and Cytostatic Agents. Pharmacol Res Perspect. 2025 Oct;13(5):e70173. doi: 10.1002/prp2.70173.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Selegiline	Unknown	10 mg	Oral
Background	Docetaxel	Small molecule	75 mg/m2	Intravenous

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

Summary

Timeline

Publications

Drugs

Indications